Second Cup dumps Jewish General Hospital franchisee over video with 'hateful remarks'
Forget iPhones, Samsung’s New Foldable Phone Is $1,200 Off For Black Friday
Jim Harbaugh, Justin Herbert and the Los Angeles Chargers celebrated in the locker room Saturday after they wrapped up a playoff spot with a 40-7 victory over the New England Patriots . But even as they realized one goal by making the postseason, Harbaugh tried to keep things focused on the road ahead by stressing: “There’s more to do.” The Chargers (10-6) go into the regular-season finale at Las Vegas knowing they will be at least the AFC’s sixth seed and avoid a trip to Buffalo for the wild-card round. Los Angeles currently is in line to face Baltimore in a Harbaugh Bowl rematch, but it has an outside shot at the fifth seed and a trip to Houston if Cincinnati beats Pittsburgh next weekend. While Harbaugh credited his players for the turnaround from five wins last year to double-digit victories this season, Herbert gave most of it to Harbaugh and first-year general manager Joe Hortiz. “They have done such a great job of getting the right guys here. You look in the locker room and everybody plays for each other,” Herbert said. “(Harbaugh’s) a competitor, and he wants to win no matter what it is. It definitely shows, and it’s the way everyone fights for him, wants to play for him, and respects him.” RELATED COVERAGE Eagles QB Tanner McKee gets 1st career TD football back with a little help from fans in the stands Like a football off McBride’s helmet, the Cardinals aren’t getting many lucky bounces these days Giants topple Colts 45-33 to eliminate Indy from the playoff race Harbaugh is the fifth coach in NFL history to win at least 10 games in his first season with two teams. He is also the eighth to make the playoffs in his first season with two teams. “Very little to do with me. If it goes right, then it’s our players. They’re doing a great job. It’s gone bad a couple times. That’s on me,” he said. “I’ve been drinking the Kool-Aid here from day one, I can’t give enough credit to Derwin James, Justin Herbert, and those two in particular. And Khalil Mack and Rashawn Slater. I mean, stalwarts. Brad Bozeman has come in. He’s been a stalwart. There’s a bunch. There’s probably, like — I counted it up early. There was maybe 15, 15 stalwarts that we had, and it’s grown since then.” Even though the Chargers are 3-5 against teams with winning records at the time they’ve played them, they are 7-1 against teams that were at or under .500. Four of those wins against opponents with losing records have come by at least 17 points, the first time since 2017 the Bolts have won that many games by as big a margin. Since halftime of their Dec. 19 game against Denver, the Chargers have outscored the Broncos and Patriots 61-13 over six quarters. “That’s the type of football we want to be playing in December, January, and hopefully on. That’s the type of football you want to be playing, especially in these big games like that. It was really good to see,” Herbert said. What’s working Offensive coordinator Greg Roman has said throughout the season it’s tough to use the full playbook when the Chargers have short drives. They came into Saturday’s game ranked 26th with only 23 possessions of at least 10 plays, but they had four against the Patriots, leading to three touchdowns and a field goal. It was the first time since Week 10 last season against Detroit they have had at least four drives of double-digit plays. What needs help Kickoff return coverage. The Chargers have allowed nine kick returns of at least 30 yards, eighth most in the league. New England’s Alex Erickson had three returns for 90 yards, including 34 and 31 yards. Stock up RB J.K. Dobbins was activated off injured reserve and provided a boost to the offense with 76 yards on 19 carries and a touchdown. Dobbins, who missed four games due to a knee injury, has set career highs in scrimmage yards (983) and rushing yards (842) in his first season with the Chargers. Stock down WR D.J. Chark was targeted four times but didn’t have a catch. Chark was signed during the offseason to provide experience and speed to a young receiver group. However, he missed the first half of the season with a hip injury and has played sparingly since his return. He has three receptions on the season. Injuries Three starters — RB Gus Edwards (ankle), LB Denzel Perryman (groin) and OG Trey Pipkins (hip) — were inactive. WR Joshua Palmer (heel) and DB Elijah Molden (shin) were injured in the second half. Key numbers 77 and 1,054 — Receptions and receiving yards by Ladd McConkey, both records for a Chargers rookie. 5 — Consecutive seasons by Herbert with at least 3,000 passing yards and 20 touchdown passes, tied with Peyton Manning and Russell Wilson for the most to start a career. 2 — Sacks by Derwin James Jr. against the Patriots, the first time in the safety’s seven-year career he has had multiple sacks in a game. What’s next The Chargers go for their first season sweep of the Raiders since 2018 in the regular-season finale. ___ AP NFL: https://apnews.com/hub/NFLWhen McLaren CEO Zak Brown first joined the Formula 1 team back in 2016, he admitted some surprise about what he found - and not in a good way. From the excitement about joining his favourite squad, the reality check of the 'chaos' he walked into was not an easy one to deal with. As he sits down exclusively with Autosport to reflect on his journey from that low point to get to where McLaren has become constructors’ champion, he admitted that the first impression was "a lot worse than I thought it was.” At the time, the struggles McLaren was facing with Honda were pretty clear to see – but the mistake that many made was thinking that its engine was its only deficit. For Brown, problems were everywhere. “I think we now know that wasn't even probably the biggest part of the issue,” added Brown, who saw problems with management, structure and sponsorship. “You had a revolving door in leadership and chaos at the board level, which has been well documented. “You had no adult supervision on the racing team and people. You've got leaders, but people need good leadership. “On-track sponsorship was at a record low and everything on the factory floor was a conspiracy theory. There was a lot of negativity. “We were way behind on development. I think there was almost an arrogance of ‘we are so good’ that we took our eye off of wind tunnels and CFDs. “So that's kind of what I walked into.” Making change Having spent the first part of his career as a sponsorship guru, Brown knew how to run a big business, but his switch to McLaren was the first time he had stepped into a management role with a racing team of such a scale. And being what he would even admit was a little bit wet behind the ears on that front meant he had to bat away any lack of self-confidence when it came to proving to the staff that he was in this for the long haul. “I'd been around racing," he said, "but actually standing up and talking to a racing team, when they're all staring at you, you could feel the: How long is this guy going to be around? “Everyone else had been around a year or two, and you could kind of feel that. So you had to portray confidence.” Brown says that the priority from day one was sorting out the senior figures, because if that was not right then everything else was doomed. “The first thing I did was change the leadership team, kind of one by one,” he said. “I didn't come in with that in mind, but I quickly identified this place needs new leadership. “Some people I hired I had worked with at JMI [the sponsorship agency founded by Brown]. Some people were brand new. And only one was an internal promotion, which was Laura [Bowden], now our CFO, because to have a great racing team, everything needs to fire on all cylinders, right? “If you're going to have great commercial success, it's got to have a huge fan base. You have got to have a great comms team to engage with the fans. You’ve got to sell sponsors to be able to hire the best people, to do a new wind tunnel. “It's not just have a great aerodynamic department. You've got to have that. But then there's everything that feeds into that.” While changes were taking place behind the scenes to give the Woking factory the management structure it needed, revolution was coming on track too. The Renault wake-up call At the end of 2017, Brown moved to end the Honda partnership and switch the squad to customer Renault engines for the 2018 season, in a change that actually proved to be an awakening moment for a team that had led itself to believe its chassis was as good as anybody else’s out there. Brown added: “That was a great wake up call, because I think everyone thought we were just bolting a new engine in and here we are. But it was actually, ‘we’ve changed that, it’s a little better, but we’ve still got some big issues’ So I think that was healthy.” What followed then were those challenging Covid 2020/2021 campaigns where off track Brown battled to shore up the finances that had left it risking collapse without the support of its shareholders. “We were definitely on the brink," said Brown. "We were paying all our bills, but we were months away, and not several months, from [shutting]. We knew we could make it through the year, but we were in a situation that if we didn't have a cash injection, we would have been at risk.” On track there was the unprecedented situation caused by the unique 2020/2021 campaigns of frozen car development where Brown felt the new team of Andreas Seidl and James Key had the good fortune to inherit a competitive package, and duly get the credit for the previous regime’s efforts. “Everyone kind of thought with the new people that had come in, Seidl, James Key ‘like, wow, look at what they've done in ‘21’ and it was actually the team before," said Brown. "So really the first time their collective work was seen was ’22.” A difficult start to that year, allied to problems Daniel Ricciardo faced, triggered concern for Brown. But the eureka moment for him that things were not where they needed to be came at that year’s French Grand Prix when a much hyped upgrade package failed to deliver. Brown said: “It didn't work, and the response from the leadership, that was not what I expected. I thought we're in trouble now. So I had some pretty serious conversations.” Over the summer break, Brown dealt with the Ricciardo issue as the team and driver reached a deal to end their partnership at the end of the year. Brown also decided, after Seidl had come to him saying he had signed a contract to join Audi, to agree to an early exit so he could make the internal change he wanted: putting current team boss Andrea Stella in charge. “I could have gone [to Seidl], ‘no, hang out your contract’," said Brown. "But it was like, no, actually, congratulations, you can join tomorrow. “I'd actually wanted Andrea Stella to run the team before I made that decision, but he had originally turned it down [over the 2019/2020 winter]. He felt he wasn't ready, and that's the type of guy Andrea is. He’s not ego-driven.” Brown recalls his second more successful attempt to convince Stella to join once it became clear that Seidl would be moving on. “I went: ‘Andrea, I really need you'," added Brown. "He tells a funny story. I was calling, he was having an espresso, and he was like, I need another espresso! “He didn’t accept it on the first call. He was like, ‘let me think about this, it is a big ask.’ But ultimately, I got him over the line.” The Stella impact Brown tasked Stella with doing a root and branches review of the racing team to help shape it in a way that he felt would work best. And, while the Italian had not been willing to shake the tree in his previous capacity as an engineer, now he was in a different role. “I asked him to look at everything," said Brown. "He'd obviously been paying attention, and he's a guy who stays in his lane of authority. But now I was like: ‘I want you to have total authority.’ “We knew the start of '23 was going to be a mess. We made some changes. James Key and Tony Salter, left, and it empowered people like Pete Prodromou, who had been a bit sidelined. “We just put the right guys back in charge, because we didn't really make many new hires. We just restructured it. We then told the media: ‘We're going to have a terrible start to ’23.' And we were spot on! “Then there was the hard part. We were getting blasted by everyone, but our partners were hanging in there, because we'd been on a nice journey, and the shareholders were totally hanging in there. “They all wanted to know, what are you doing? You need to fix this! But I never felt that they weren't going to give me the opportunity.” That beginning of 2023 offered a disconnect between the results the team was delivering on track and the rapid rate of progress with upgrades that were taking place at the factory. Brown said: “We started to see a rate development. Then we had this weird dynamic of getting killed on the race track and publicly slaughtered, with a quiet confidence back at the factory. “I think what was good was we knew we were going to be bad in ‘23 and we called our shot. So it wasn't like we were scratching our head. We knew we weren't going to be good. “At this point, we had got plenty of sponsorship and there was a lot of belief in Andrea's leadership, and that leadership team were firing on all cylinders, right? Across finance, HR, comms, commercial. We were very united, and it made us stronger.” The final steps Confirmation of the upwards trajectory came at the 2023 Austrian Grand Prix, when a planned big upgrade did the job. “Andrea kind of called his shot at Austria, which was out of character for him,” added Brown. “He was like, ‘oh, that's going to be a big one.’ “We rolled it out on Lando's car. It was strong, but then afterwards we knew Lando was always good there, so was it him or was it the car? But then at Silverstone it was 'wow'.” From that moment on, McLaren has built on its form. Developments have worked and the progress has been steady so that when that Miami upgrade arrived in May this year, it catapulted the squad to the front. Brown thinks McLaren is now back to the kind of team that he originally fell in love in. “I think we're on our A-game now,” he said. “We've got the best sponsor portfolio on the grid. I think we have record revenues. We are profitable, which is a sign of the success we've had on track. “But we go racing for trophies, not for economics. I think we're back to the McLaren I knew, which was, 'oh did you see what McLaren did on track or off track.' And I put it all down to people at the end of the day. “We've all got great wind tunnels. We've all got great CFD. But it's the people that make the difference.” And the key focus for Brown now, as his squad celebrates that first F1 constructors’ title since 1998, is ensuring it doesn’t drop the ball now. “If you look at some of the other teams out there, that have got great technology, great drivers, and kind of slid backwards, I think it's because the culture's not where it needs to be,” he said. “My primary goal now is to bottle up what we have right now, add to it where I can, but not let anyone eat, as Andrea calls them, the poison biscuits – which is the politics internally, or the politics that people try and lob in. “It's easy to happen when we have a bad weekend or a weekend we could have done better, but the way Andrea is able to pick the team up and go 'don't go there' it is amazing. It's don't start blaming each other. We're a team. It's just kept us really solid.” In this article Jonathan Noble Formula 1 Be the first to know and subscribe for real-time news email updates on these topics Subscribe to news alerts
WASHINGTON (AP) — President-elect Donald Trump’s allies on Capitol Hill rallied around Pete Hegseth , Trump’s Pentagon pick, on Thursday even as new details surfaced about allegations that he had sexually assaulted a woman in 2017. The GOP embrace of Hegseth came as another controversial Trump nominee, Matt Gaetz, withdrew from consideration for attorney general. Gaetz said it was clear he had become a “distraction" amid pressure on the House to release an ethics report about allegations of his own sexual misconduct. An attorney for two women has said that his clients told House Ethics Committee investigators that Gaetz paid them for sex on multiple occasions beginning in 2017, when Gaetz was a Florida congressman. Fresh questions over the two nominees' pasts, and their treatment of women, arose with Republicans under pressure from Trump and his allies to quickly confirm his Cabinet. At the same time, his transition has so far balked at the vetting and background checks that have traditionally been required. While few Republican senators have publicly criticized any of Trump's nominees, it became clear after Gaetz's withdrawal that many had been harboring private concerns about him. Oklahoma Sen. Markwayne Mullin, who served with Gaetz in the House, said it was a “positive move.” Mississippi Sen. Roger Wicker said it was a “positive development.” Maine Sen. Susan Collins said Gaetz “put country first and I am pleased with his decision.” After meeting with Hegseth, though, Republicans rallied around him. “I think he’s going to be in pretty good shape,” said Wicker, who is expected to chair the Senate Armed Services Committee in the next Congress. Republican senators' careful words, and their early reluctance to publicly question Trump's picks, illustrated not only their fear of retribution from the incoming president but also some of their hopes that the confirmation process can proceed normally, with proper vetting and background checks that could potentially disqualify problematic nominees earlier. Gaetz withdrew after meeting with senators on Wednesday. Sen. Thom Tillis said Gaetz was “in a pressure cooker” when he decided to withdraw, but suggested that it would have little bearing on Trump’s other nominees. “Transactions — one at a time,” he said. As the Hegseth nomination proceeds, Republicans also appear to be betting that they won't face much backlash for publicly setting aside the allegations of sexual misconduct — especially after Trump won election after being found liable for sexual abuse last year. Hegseth held a round of private meetings alongside incoming Vice President JD Vance on Thursday in an attempt to shore up support and told reporters afterward: “The matter was fully investigated and I was completely cleared, and that’s where I’m gonna leave it.” A 22-page police report report made public late Wednesday offered the first detailed account of the allegations against him. A woman told police that she was sexually assaulted in 2017 by Hegseth after he took her phone, blocked the door to a California hotel room and refused to let her leave. The report cited police interviews with the alleged victim, a nurse who treated her, a hotel staffer, another woman at the event and Hegseth. Hegseth’s lawyer, Timothy Palatore, said the incident was “fully investigated and police found the allegations to be false.” Hegseth paid the woman in 2023 as part of a confidential settlement to head off the threat of what he described as a baseless lawsuit, Palatore has said. Wicker played down the allegations against Hegseth, a former Fox News host, saying that “since no charges were brought from the authorities, we only have press reports.” Sen. Bill Hagerty, R-Tenn., said after his meeting with Hegseth that he "shared with him the fact that I was saddened by the attacks that are coming his way.” Hagerty dismissed the allegations as “a he-said, she-said thing” and called it a “shame” that they were being raised at all. The senator said attention should instead be focused on the Defense Department that Hegseth would head. It's one of the most complex parts of the federal government with more than 3 million employees, including military service members and civilians. Sexual assault has been a persistent problem in the military, though Pentagon officials have been cautiously optimistic they are seeing a decline in reported sexual assaults among active-duty service members and the military academies. Wyoming Sen. John Barrasso, who will be the No. 2 Republican in the Senate next year, said after his meeting with Hegseth that the nominee is a strong candidate who “pledged that the Pentagon will focus on strength and hard power – not the current administration’s woke political agenda.” Senate Republicans are under pressure to hold hearings once they take office in January and confirm nominees as soon as Trump is inaugurated, despite questions about whether Trump’s choices will be properly screened or if some, like Hegseth, have enough experience for the job. Senate Armed Services Chairman Jack Reed, who will be the top Democrat on the panel next year, said the reports on Hegseth “emphasized the need for a thorough investigation by the FBI on the background of all the nominees.” It takes a simple majority to approve Cabinet nominations, meaning that if Democrats all opposed a nominee, four Republican senators would also have to defect for any Trump choice to be defeated. Trump has made clear he’s willing to put maximum pressure on Senate Republicans to give him the nominees he wants – even suggesting at one point that they allow him to just appoint his nominees with no Senate votes. But senators insist, for now, that they are not giving up their constitutional power to have a say. “The president has the right to make the nominations that he sees fit, but the Senate also has a responsibility for advice and consent,” said Republican Sen. Mike Rounds of South Dakota. In the case of Gaetz, he said, “I think there was advice offered rather than consent.” Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. Get local news delivered to your inbox!BNP Paribas Financial Markets lifted its stake in Integra LifeSciences Holdings Co. ( NASDAQ:IART – Free Report ) by 824.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 111,775 shares of the life sciences company’s stock after acquiring an additional 99,685 shares during the quarter. BNP Paribas Financial Markets owned 0.14% of Integra LifeSciences worth $2,031,000 as of its most recent filing with the Securities & Exchange Commission. Several other hedge funds have also recently made changes to their positions in IART. Cooke & Bieler LP lifted its holdings in Integra LifeSciences by 12.4% in the second quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock valued at $102,406,000 after acquiring an additional 388,710 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Integra LifeSciences by 0.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock worth $52,014,000 after purchasing an additional 12,766 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Integra LifeSciences by 15.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company’s stock worth $17,158,000 after purchasing an additional 125,620 shares during the period. D. E. Shaw & Co. Inc. boosted its holdings in shares of Integra LifeSciences by 64.6% in the second quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock worth $24,925,000 after buying an additional 335,557 shares during the last quarter. Finally, AQR Capital Management LLC grew its position in Integra LifeSciences by 90.9% during the second quarter. AQR Capital Management LLC now owns 611,798 shares of the life sciences company’s stock valued at $17,436,000 after buying an additional 291,326 shares during the period. 84.78% of the stock is owned by hedge funds and other institutional investors. Integra LifeSciences Stock Up 1.0 % Shares of IART opened at $24.10 on Friday. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $45.42. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $1.86 billion, a PE ratio of -267.75, a price-to-earnings-growth ratio of 0.82 and a beta of 1.15. The business’s 50 day moving average is $21.44 and its 200 day moving average is $23.88. Insider Activity In related news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares in the company, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink . Company insiders own 3.10% of the company’s stock. Analysts Set New Price Targets Several research analysts have recently weighed in on the stock. Truist Financial dropped their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Bank of America lowered their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th. Morgan Stanley initiated coverage on Integra LifeSciences in a report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target for the company. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Finally, Citigroup boosted their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $23.00. Read Our Latest Report on Integra LifeSciences Integra LifeSciences Profile ( Free Report ) Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. See Also Five stocks we like better than Integra LifeSciences What Are Some of the Best Large-Cap Stocks to Buy? Fast-Growing Companies That Are Still Undervalued What Makes a Stock a Good Dividend Stock? Top Cybersecurity Stock Picks for 2025 Bank Stocks – Best Bank Stocks to Invest In Archer or Joby: Which Aviation Company Might Rise Fastest? Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. ( NASDAQ:IART – Free Report ). Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter ."Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.
Developers will have to show that their project either helps reduce the amount of non-recyclable waste going to landfill, or replaces an older, less efficient incinerator. The move forms part of the Government’s drive to increase recycling rates, which have held at about 45% of household waste since 2015. Environment minister Mary Creagh said: “For far too long, the nation has seen its recycling rates stagnate and relied on burning household waste, rather than supporting communities to keep resources in use for longer. “That ends today, with clear conditions for new energy from waste plants – they must be efficient and support net zero and our economic growth mission, before they can get the backing needed to be built.” Developers will also have to ensure their incinerators are ready for carbon capture technology, and demonstrate how the heat they produce can be used to help cut heating bills for households. The Government expects that its “crackdown” on new incinerators will mean only a limited number are built, while still reducing the amount of waste sent to landfill and enabling the country to process the waste it produces. The Department for the Environment, Food and Rural Affairs said the country was almost at the point where it had enough waste facilities to handle non-recyclable rubbish, and so had limited need for new incinerators. But the proposals stop short of the plans included in the Conservatives’ 2024 manifesto, which committed to a complete ban on new incinerators due to their “impact on local communities” and declining demand as recycling increased.NEW YORK , Dec. 10, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Macy's, Inc. (NYSE: M) resulting from allegations that Macy's may have issued materially misleading business information to the investing public. So What: If you purchased Macy's securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=31645 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. What is this about: On November 25, 2024 , The New York Times published an article entitled "Macy's Discovers Employee Hid Millions in Delivery Expenses." This article stated that "Macy's said on Monday that an employee had "intentionally" misstated and hidden up to $154 million in delivery expenses over the past few years, forcing the retailer to delay a much-anticipated earnings report that Wall Street uses to gauge the strength of holiday shopping." On this news, the price of Macy's, Inc. stock fell 2.2% on November 25, 2024 . Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View original content to download multimedia: https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-macys-inc-investors-to-inquire-about-securities-class-action-investigation--m-302327927.html SOURCE THE ROSEN LAW FIRM, P. A.EVANSVILLE, Ind. (AP) — Tayshawn Comer scored 18 points as Evansville beat Campbell 66-53 on Sunday night. Comer had six rebounds and six assists for the Purple Aces (3-4). Cameron Haffner scored 16 points and added six rebounds. Gabriel Pozzato shot 3 for 5, including 2 for 3 from beyond the arc to finish with 10 points. Jasin Sinani led the way for the Fighting Camels (3-4) with 22 points. Colby Duggan added 11 points and Nolan Dorsey totaled eight points, seven rebounds and four steals. Evansville took the lead with 1:45 left in the first half and never looked back. The score was 34-28 at halftime, with Haffner racking up eight points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
Even with access to blockbuster obesity drugs, some people don't lose weight
Pep Guardiola looks defeated as he delivers grim Man City injury update before Juventus and Man UtdLAS VEGAS , Dec. 10, 2024 /PRNewswire/ -- The veterinary vaccines market is experiencing robust growth driven by factors such as the rising prevalence of zoonotic diseases, increasing concerns about antimicrobial resistance in animals, and a growing demand for safe and efficient food production. Additionally, the heightened emphasis on minimizing animal morbidity and mortality from preventable diseases through regular immunization is significantly contributing to the market's revenue expansion during the forecast period (2024–2030). DelveInsight's Veterinary Vaccines Market Insights report provides the current and forecast market analysis, individual leading veterinary vaccine companies' market shares, challenges, veterinary vaccines market drivers, barriers, trends, and key market veterinary vaccine companies in the market. Key Takeaways from the Veterinary Vaccines Market Report As per DelveInsight estimates, North America is anticipated to dominate the global veterinary vaccines market during the forecast period. In the type segment of the veterinary vaccines market, the viral vector category had a significant share in 2023. Notable veterinary vaccine companies such as Hester Biosciences Limited, Boehringer Ingelheim International GmbH, Zoetis Services LLC, Elanco, Merck & Co., Inc., Indian Immunologicals Ltd., Phibro Animal Health Corporation, Biogénesis Bagó®, HIPRA, ARKO, Kyoto Biken Laboratories, Inc., Vaxxinova® International BV, Dyntec s. r. o., Brilliant Bio Pharma, BioTestLab, Virbac, KBNP, BIMEDA, Shchelkovo biocombinat, VAKSINDO ANIMAL HEALTH PVT. LTD, and several others, are currently operating in the veterinary vaccines market. In September 2022 , Boehringer Ingelheim launched Fencovis® which is the first vaccine against calf disease. In June 2022 , India's first homegrown COVID-19 vaccine Anocovax for animals, produced by the ICAR-National Research Centre on Equines (NRCE) was launched in India . In April 2022 , Ceva Animal Health launched the IBird vaccine against Infectious Bronchitis in India . To read more about the latest highlights related to the veterinary vaccines market, get a snapshot of the key highlights entailed in the Global Veterinary Vaccines Market Report Veterinary Vaccines Overview Veterinary vaccines are a cornerstone of animal healthcare, pivotal in preventing and controlling infectious diseases in domestic and wild animals. These vaccines bolster the immune system of animals, enabling them to combat pathogens effectively and reducing the spread of diseases. By protecting livestock, poultry, and pets, veterinary vaccines safeguard animal health, promote agricultural productivity, and ensure food security. They are also vital in managing zoonotic diseases, which can be transmitted from animals to humans, thus contributing to public health. Examples include vaccines for rabies, foot-and-mouth disease, and avian influenza, which protect animal populations and reduce the risk of epidemics. Advancements in biotechnology have significantly improved the efficacy and safety of veterinary vaccines. Innovations such as recombinant DNA technology, subunit vaccines, and mRNA-based approaches have led to the development of more targeted and effective immunizations with minimal side effects. Moreover, the use of adjuvants and delivery systems like nanocarriers has enhanced vaccine stability and immunogenicity. As the global demand for sustainable and ethical animal farming grows, the focus on vaccines as a preventive measure over antibiotics is increasing, aligning with the goals of One Health initiatives. These efforts emphasize the interconnectedness of human, animal, and environmental health, underscoring the critical role of veterinary vaccines in fostering a healthier world. Veterinary Vaccines Market Insights North America is projected to dominate the global veterinary vaccines market, driven by its robust infrastructure, advanced research capabilities, and widespread adoption of preventive veterinary healthcare practices. The region boasts a well-established veterinary healthcare system, including a high number of veterinary clinics and hospitals equipped with state-of-the-art facilities. Additionally, the presence of leading vaccine manufacturers, such as Zoetis and Merck Animal Health, fosters continuous innovation and availability of effective vaccines. Factors such as a growing pet population, increasing awareness of zoonotic diseases, and rising expenditure on pet healthcare further contribute to North America's leadership in this sector. The regulatory environment in the region also facilitates the rapid approval and distribution of vaccines, ensuring that animals, both livestock and companions, have timely access to preventive solutions. Furthermore, the region's large livestock industry plays a crucial role in driving demand for veterinary vaccines to safeguard animal health and ensure food safety. The United States , as a significant player in the global meat and dairy trade, places considerable emphasis on maintaining the health of its animal herds. Vaccines against diseases such as bovine viral diarrhea, avian influenza, and porcine reproductive and respiratory syndrome are in high demand to prevent economic losses in the livestock sector. Canada's initiatives to improve animal health standards and prevent disease outbreaks further bolster the regional market. As awareness grows about the role of veterinary vaccines in preventing antibiotic resistance and improving overall animal welfare, North America is expected to maintain its dominance in the veterinary vaccines market. To know more about why North America is leading the market growth in the veterinary vaccines market, get a snapshot of the Veterinary Vaccines Market Outlook Veterinary Vaccines Market Dynamics The veterinary vaccines market plays a pivotal role in ensuring the health and productivity of animals, catering to both companion animals and livestock. With a growing emphasis on animal welfare, zoonotic disease prevention, and food safety , the demand for effective vaccines continues to rise. Additionally, the industry is driven by the need to mitigate the economic impact of livestock diseases , which can cause significant losses for farmers and the agriculture industry. Vaccines help reduce the reliance on antibiotics, aligning with global efforts to combat antimicrobial resistance. One of the major dynamics influencing the veterinary vaccines market is the increasing prevalence of zoonotic diseases , which can transfer from animals to humans. This has spurred investments in research and development for innovative vaccines. Advances in biotechnology , such as recombinant DNA technology and gene editing, have enabled the development of more effective and targeted vaccines. The advent of next-generation vaccines, including DNA and RNA-based solutions, offers a promising horizon for the industry, especially in addressing complex diseases. Market growth is also shaped by regulatory frameworks , which can vary significantly across regions. While stringent regulations ensure vaccine safety and efficacy, they can also pose challenges for new entrants and prolong time-to-market for innovative solutions. Additionally, the cost of vaccine development and distribution , particularly in developing economies, remains a significant barrier. However, government initiatives and collaborations with global organizations , such as the World Organisation for Animal Health (OIE), are facilitating vaccine access in underserved regions. The companion animal segment is experiencing notable growth, driven by the rising pet population and increasing awareness among pet owners about preventive healthcare. In parallel, the livestock segment continues to dominate, propelled by the growing global demand for meat, milk, and other animal-derived products . The focus on sustainable livestock farming and disease prevention further fuels the demand for vaccines, as farmers aim to enhance productivity while reducing environmental impacts. In conclusion, the veterinary vaccines market is characterized by rapid technological advancements, a growing focus on zoonotic disease control, and evolving consumer awareness. While challenges such as high development costs and regulatory hurdles persist, opportunities abound in the form of emerging markets, novel technologies, and increasing collaborations within the global health ecosystem. This dynamic landscape underscores the critical role of veterinary vaccines in ensuring animal and human health alike. Get a sneak peek at the veterinary vaccines market dynamics @ Veterinary Vaccines Market Dynamics Analysis Veterinary Vaccines Market Assessment Veterinary Vaccines Market Segmentation Veterinary Vaccines Market Segmentation By Type: Inactivated Veterinary Vaccines, Live-Attenuated Veterinary Vaccines, Subunit Veterinary Vaccines, Recombinant Veterinary Vaccines, and Viral Vector Veterinary Vaccines Veterinary Vaccines Market Segmentation By Indication: Viral, Bacterial, and Others Veterinary Vaccines Market Segmentation By Animal Group: Poultry, Livestock, Companion Animals, and Others Veterinary Vaccines Market Segmentation By End User: Veterinary Clinics and Others Veterinary Vaccines Market Segmentation By Geography : North America , Europe , Asia-Pacific , and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the veterinary vaccines market are set to emerge as the trendsetter explore @ Veterinary Vaccines Companies Table of Contents Interested in knowing the veterinary vaccines market by 2030? Click to get a snapshot of the Veterinary Vaccines Market Trends Related Reports Vaccines Market Vaccines Market Insights, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key vaccines companies, including GlaxoSmithKline, Bharat Biotech, AstraZeneca, Bavarian Nordic A/S, BioNTech, Sanofi, Merck & Co., Inc, Pfizer Inc, Moderna, Meiji Holdings Co., Ltd., EMERGENT, CSL Limited, Johnson & Johnson, VBI Vaccines Inc., Valneva SE., Novavax, CanSinoBIO, Biokangtai, Dynavax Technologies, Zhi Fei Biological , among others. Veterinary Diagnostic Imaging Market Veterinary Diagnostic Imaging Market Insights, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key veterinary diagnostic imaging companies, including Canon Medical Systems ANZ Pty Limited, Carestream Health., Epica Animal Health, ESAOTE SPA, FUJIFILM Holdings America Corporation, Hallmarq Veterinary Imaging, IDEXX Laboratories Inc., IMV., General Electric Company, Mindray Group, Heska Corporation, Siemens Healthcare Limited, Konica Minolta Inc., E.I. Medical Imaging., Sedecal, DRAMIŃSKI S. A., Clear Ray Imaging., SIUI, Sonoscape Medical Corp., Reproscan , among others. Animal Nutrition Market Animal Nutrition Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key animal nutrition companies, including Nutreco, Alltech, Dow, Novozymes, Tata Chemicals Ltd., ADM, Adisseo Cargill, Incorporated, DuPont, Kemin Industries, Inc., Phibro Animal Health Corporation, Rossari Biotech Limited, Avitech Nutrition Pvt. Ltd., Aries Agro Limited, Advanced Enzymes, Glanbia plc., Zinpro Corp., NOVUS INTERNATIONAL, Biovet Private Ltd., Balchem Inc., among others. Animal Intestinal Health Market Animal Intestinal Health Market Insights, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key animal intestinal health companies, including Anco Animal Nutrition Competence GmbH, Elanco Animal Health Incorporated, Royal DSM, Evonik, Kemin Industries, Inc., Balchem Corp., Nutreco, Alltech, Tata Chemicals Ltd., Adisseo Cargill, Phibro Animal Health Corporation, Rossari Biotech Limited, Avitech Nutrition Pvt. Ltd., Aries Agro Limited, Advanced Enzymes, Glanbia plc., Zinpro Corp., NOVUS INTERNATIONAL, Balchem Inc., Novozymes , among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 https://www.delveinsight.com/medical-devices Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg SOURCE DelveInsight Business Research, LLPWe have much to be thankful for this year. One of those things is the defeat of Proposition 5, which would have made it easier to raise property taxes. Affecting homes, apartment buildings and commercial real estate, Prop. 5 would have burdened Californians with a higher cost of housing and a higher cost of living. We can all be grateful that voters resoundingly said no to that. It is also a good reminder of why we Californians should be thankful for Proposition 13, the 1978 initiative that put sensible limits on increases in property taxes, and put those limits into the state constitution. Prior to Proposition 13, property taxes were out of control. The tax rate throughout California averaged 2.67% of assessed value, and assessed value was regularly updated to match current market value. As inflation and market factors pushed property values higher and higher, homeowners received property tax bills based on their “paper profits,” with no limits on annual increases. Some properties were reassessed 50 to 100 percent higher in just one year, so their owners’ tax bills skyrocketed, often beyond the homeowners’ ability to pay. In one year in Los Angeles County alone, 400,000 people had not paid their property tax because they didn’t have the money, running the risk of being forced out of their homes. Retired people on fixed incomes were among the hardest hit. Many had paid off their mortgages yet faced losing their homes because they couldn’t afford the annual property tax bill. Then, just as millions of Californians were at risk of being driven out of their homes, Howard Jarvis gathered more than 1.5 million signatures to qualify a statewide initiative that would finally end excessive taxation and protect the security of property ownership — Proposition 13. An overwhelming majority of Californian voters voted for Proposition 13 despite a campaign of scare tactics. It turned out that nothing scared Californians more than opening their property tax bill. Proposition 13 made property taxes predictable and manageable. First, Prop. 13 cut the property tax rate from a statewide average of 2.67% down to 1%. To this day, even new homeowners are saving money compared to what they would have been paying. Check out the Howard Jarvis Taxpayers Association’s calculator at GuessingGame.org for a look at how much you’d be paying in annual property taxes if Prop. 13 had never passed. Second, it limits the annual increase in assessed value to the rate of inflation, capped at 2%. Under Prop. 13, even if a property doubles in market value in a single year, its “taxable value,” against which the assessor applies the 1% tax rate, can only be increased a maximum of 2% per year. Related Articles Opinion Columnists | Gavin Newsom should stop showboating and just do his job as governor of California Opinion Columnists | Will Trump double down on or fix Biden’s antitrust insanity? Opinion Columnists | Rafael Perez: Americans really need to relax and stop taking national politics so seriously Opinion Columnists | Elon Musk gets it: America’s legal immigration process need to change Opinion Columnists | Susan Shelley: The mundane reality of UFOs Third, Prop. 13 requires reassessment of property when it changes hands. This provides local governments with a stable and predictable source of tax revenue, which has grown virtually every year since 1978 in percentages that exceed inflation and population growth. Proposition 13 also protected taxpayers by requiring a two-thirds vote of the state legislature to raise taxes and by giving Californians the right to vote on local tax increases, with a two-thirds vote required to pass certain tax hikes. The two-thirds vote is particularly critical when it comes to property taxes. Because people can lose their homes if they can’t pay the property tax bill, the vote threshold must be higher than a simple majority of voters, many of whom are voting on a tax they won’t personally have to pay, at least not directly. It’s this two-thirds protection that Proposition 5 attempted to destroy. It’s hard enough to pay the bills in this state without politicians trying to raise taxes in every election. We’re thankful that Proposition 13 is protecting Californians, every day. Jon Coupal is president of the Howard Jarvis Taxpayers Association.